- Home
- IMNN vs PAVM Comparison
IMNN vs PAVM Comparison
Compare IMNN & PAVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- PAVM
- Stock Information
- Founded
- IMNN 1982
- PAVM 2014
- Country
- IMNN United States
- PAVM United States
- Employees
- IMNN N/A
- PAVM N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- PAVM Medical/Dental Instruments
- Sector
- IMNN Health Care
- PAVM Health Care
- Exchange
- IMNN Nasdaq
- PAVM Nasdaq
- Market Cap
- IMNN 12.1M
- PAVM 12.0M
- IPO Year
- IMNN 1985
- PAVM 2016
- Fundamental
- Price
- IMNN $0.60
- PAVM $0.63
- Analyst Decision
- IMNN Strong Buy
- PAVM Strong Buy
- Analyst Count
- IMNN 2
- PAVM 1
- Target Price
- IMNN $15.50
- PAVM $19.50
- AVG Volume (30 Days)
- IMNN 237.6K
- PAVM 147.3K
- Earning Date
- IMNN 05-12-2025
- PAVM 05-15-2025
- Dividend Yield
- IMNN N/A
- PAVM N/A
- EPS Growth
- IMNN N/A
- PAVM N/A
- EPS
- IMNN N/A
- PAVM 0.50
- Revenue
- IMNN N/A
- PAVM $2,995,000.00
- Revenue This Year
- IMNN N/A
- PAVM N/A
- Revenue Next Year
- IMNN N/A
- PAVM $457.25
- P/E Ratio
- IMNN N/A
- PAVM $1.27
- Revenue Growth
- IMNN N/A
- PAVM 22.14
- 52 Week Low
- IMNN $0.64
- PAVM $0.55
- 52 Week High
- IMNN $3.65
- PAVM $2.42
- Technical
- Relative Strength Index (RSI)
- IMNN 24.71
- PAVM 39.87
- Support Level
- IMNN $0.60
- PAVM $0.65
- Resistance Level
- IMNN $1.08
- PAVM $0.78
- Average True Range (ATR)
- IMNN 0.08
- PAVM 0.07
- MACD
- IMNN -0.02
- PAVM -0.01
- Stochastic Oscillator
- IMNN 3.12
- PAVM 1.33
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.